|Table of Contents|

Role of salvage radiotherapy for regional lymph node recurrence after radical surgery in advanced gastric cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 01
Page:
99-103
Research Field:
Publishing date:

Info

Title:
Role of salvage radiotherapy for regional lymph node recurrence after radical surgery in advanced gastric cancer
Author(s):
Luan Honghui; Ji Shaochun; Li Shenglan; Niu Guangyu; Peng Jiaming; Xue Dong
Department of Radiotherapy，Jiamusi Central Hospital,Heilongjiang Jiamusi 154002，China.
Keywords:
radiotherapy; lymph nodes; recurrence; stomach neoplasms
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2017.01.027
Abstract:
Objective：To evaluate the role of salvage radiotherapy (RT） for the treatment of regional lymph node recurrence (RLNR） after radical surgery in advanced gastric cancer.Methods：We retrospectively analyzed medical records of 26 patients who underwent salvage treatment after diagnosis of RLNR between 2005 and 2011.Patients with peritoneal seeding or distant metastasis were excluded.Eighteen patients received RT with or without chemotherapy and the other 8 did chemotherapy only without RT.A three-dimensional conformal RT was performed with median dose of 56 Gy (range，46 to 60 Gy).Results：With a median follow-up of 20 months (range，4 to 57 months)，median overall survival (OS） and progression-free survival (PFS） after diagnosis of RLNR were 29 months and 12 months in all patients.Radiotherapy (P=0.007） and disease-free interval (P=0.030） were statistically significant factors for OS in multivariate analysis.Median OS was 36 months in patients who received RT and 16 months in those who did not.Furthermore，delivery of RT (P<0.001)，complete remission after salvage treatment and performance status were associated with a significantly better PFS.Gastrointestinal toxicities from RT were mild in most patients.Conclusion：Salvage RT combined with systemic chemotherapy may be an effective treatment managing RLNR from advanced gastric cancer.

References:

［1］DeManzoni G，Baiocchi GL，Framarini M，et al.The SICGIRCG 2013 consensus conference on gastriccancer［J］.Cancer，2014，66(1)：1-6.
［2］Jung KW，Park S，Kong HJ，et al.Cancer statistics in Korea：incidence，mortality，survival，and prevalence in 2009［J］.Cancer Res Treat，2012，44：11-24.
［3］Zhang XT.Current status of clinical research on gastric cancer in China［J］.Chin J Gastro Intestinal Surg，2013，16(6）：521-523.
［4］Chang JS，Lim JS，Noh SH，et al.Patterns of regional recurrence after curative D2 resection for stage III(N3）gastric cancer：implications for postoperative radiotherapy［J］.Radiother Oncol，2012,104：367-373.
［5］Li JH，Zhang SW，Liu J，et al.Review of clinical investigation on recurrence of gastric cancer following curative resection［J］.Chin Med J(Engl)，2012，125：1479-1495.
［6］Macdonald JS，Smalley SR，Benedetti J，et al.Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction［J］.N Engl J Med，2001，345：725-730.
［7］Niu JH,Feng GK,Cong L,et al.Domestic Meta analysis of capecitabine with other drugs as neoadjuvant therapy in advanced gastric cancer［J］.Chin J Cancer Prev Treat，2014，24（4）：304-308.［牛建花，冯光坤，丛亮，等.中国进展期胃癌含卡培他滨新辅助化疗初步研究Meta分析［J］.中华肿瘤防治杂志，2014，24（4）：304-308.］
［8］Hu JK,Chen XZ.Pay attention to the treatment and prognosis of different stages of gastric carcinoma［J］.Chin J Base and Clinics in General Surg，2014，21(1)：1-6.［胡建坤，陈心足.重视胃癌不同分型分期的治疗和预后［J］.中国普外基础与临床杂志，2014，21(1)：1-6.］
［9］ Ha TK，Kwon SJ.Clinicopathological characteristics for type of recurrence in gastric cancer patients［J］.J Korean Gastric Cancer Assoc，2007，7：23-30.
［10］Eom BW，Yoon H，Ryu KW，et al.Predictors of timing and patterns of recurrence after curative resection for gastric cancer［J］.Dig Surg，2010，27：481-486.
［11］Sun J，Sun YH，Zeng ZC，et al.Consideration of the role of radiotherapy for abdominal lymph node metastases in patients with recurrent gastric cancer［J］.Int J Radiat Oncol Biol Phys，2010，77：384-391.
［12］Koizumi W，Nakayama N，Tanabe S，et al.A multicenter phase II study of combined chemotherapy with docetaxel，cisplatin，and S-1 in patients with unresectable or recurrent gastric cancer(KDOG 0601)［J］.Cancer Chemother Pharmacol，2012，69：407-413.
［13］Choi YH，Oh SC，Kim JS，et al.A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment：a Korean Cancer Study Group protocol ST06-02［J］.Cancer Chemother Pharmacol，2012，70：665-672.
［14］Kim MS，Yoo SY，Cho CK，et al.Stereotactic body radiotherapy for isolated para-aortic lymph node recurrence after curative resection in gastric cancer［J］.J Korean Med Sci，2009，24：488-492.
［15］Takemura N，Saiura A，Koga R，et al.Long-term outcomes after surgical resection for gastric cancer liver metastasis：an analysis of 64 macroscopically complete resections［J］.Langenbecks Arch Surg，2012，397：951-957.
［16］Makino H，Kunisaki C，Izumisawa Y，et al.Indication for hepatic resection in the treatment of liver metastasis from gastric cancer［J］.Anticancer Res，2010，30：2367-2376.
［17］Tsujimoto H，Ichikura T，Ono S，et al.Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer［J］.Hepatol Int，2010，4：406-413.
［18］Kunz PL，Gubens M，Fisher GA，et al.Long-term survivors of gastric cancer：a California population-based study［J］.J Clin Oncol，2012，30：3507-3515.
［19］Kim TH，Park SR，Ryu KW，et al.Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection［J］.Int J Radiat Oncol Biol Phys，2012，84：e585-592.
［20］Lee J，Lim DH，Kim S，et al.Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection：the ARTIST trial［J］.J Clin Oncol，2012，30：268-273.
［21］Lee DJ，Sohn TS，Lim DH，et al.Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer［J］.Cancer Chemother Pharmacol，2012，69：1333-1338.

Memo

Memo:
-
Last Update: 2016-12-01